Peptide stacking — combining two or more research peptides in a coordinated protocol — is a well-established approach in preclinical research. The rationale is mechanistic complementarity: peptides targeting different pathways can address a research objective more comprehensively than any single compound. This guide covers the most-researched peptide stacks for Indian researchers in 2026, with dosing rationale and sourcing notes.
Before preparing any stack, use our BAC water reconstitution calculator to ensure accurate dosing for each peptide in your protocol.
Stack 1: BPC-157 + TB-500 — The Recovery Stack
The BPC-157 and TB-500 combination is the most extensively studied peptide stack in musculoskeletal and soft tissue research. Their mechanisms are genuinely complementary: BPC-157 upregulates growth factor receptors (particularly VEGFR2 and EGF receptor) and directly promotes fibroblast migration to injury sites, while TB-500 (Thymosin Beta-4) sequesters G-actin and promotes systemic cell migration, angiogenesis, and anti-inflammatory signalling via actin remodelling.
BPC-157 excels at local tissue repair — tendon-to-bone junctions, gut lining, ligamentous injury — while TB-500's systemic distribution via the lymphatic system makes it effective for injuries at sites distant from the injection point. Together, they address both the local repair microenvironment and systemic recovery signalling.
Research dosing: BPC-157 250–500 mcg/day + TB-500 2–2.5 mg twice weekly. Administered as separate injections; subcutaneous at or near the research site for BPC-157, systemic for TB-500. See our recovery peptides page for both products.
Stack 2: CJC-1295 + Ipamorelin — The GH Stack
The CJC-1295 and Ipamorelin combination targets growth hormone secretion through two independent axes: CJC-1295 is a GHRH analogue that stimulates the pituitary somatotrophs via the GHRH receptor, while Ipamorelin is a selective ghrelin mimetic that activates the GHS-R1a receptor. Activating both receptors simultaneously produces a synergistic GH pulse that is larger than either peptide achieves alone — a well-documented pharmacological phenomenon across multiple studies.
The Ipamorelin component is particularly valued for its selectivity: unlike older secretagogues, it does not significantly elevate cortisol or prolactin, making it cleaner for GH research. CJC-1295 with DAC (drug affinity complex) extends the half-life to several days, while CJC without DAC (also called Mod GRF 1-29) produces a shorter, more pulsatile profile more closely mimicking natural GH physiology.
Research dosing: CJC-1295 (no DAC) 100 mcg + Ipamorelin 100–200 mcg, administered together via subcutaneous injection, typically timed around sleep or fasting windows to align with natural GH pulsatility.
Stack 3: Retatrutide — The Fat Loss Stack
Retatrutide operates as a triple agonist — GLP-1, GIP, and glucagon receptors — and in preclinical and early clinical research has demonstrated the most substantial fat mass reduction of any peptide in its class. For fat loss-focused research protocols, Retatrutide as a monotherapy is a complete approach, but researchers have also studied it alongside GHK-Cu for skin and connective tissue remodelling that accompanies significant body composition changes.
The glucagon receptor component distinguishes Retatrutide from semaglutide and tirzepatide by adding direct hepatic fat-burning activity and thermogenic effects, which may explain the superior fat mass reduction observed in research versus GLP-1-only compounds.
Research dosing: Retatrutide 2–12 mg/week subcutaneous, dose-escalated over 4–8 weeks. Titration is essential due to GI effects at higher doses. Available in our fat loss peptides collection.
Stack 4: Epithalon + MOTS-C — The Longevity Stack
Epithalon is a tetrapeptide that activates telomerase and has been shown to lengthen telomeres in aged cells, reducing DNA damage markers and extending cellular lifespan in multiple animal models. Combined with MOTS-C — the mitochondrial peptide that activates AMPK and restores mitochondrial metabolic efficiency — this stack targets two of the most researched hallmarks of ageing: telomere attrition and mitochondrial dysfunction.
The rationale is that nuclear genomic stability (Epithalon via telomerase) and mitochondrial metabolic integrity (MOTS-C via AMPK) are independent axes of cellular ageing that can be addressed simultaneously without mechanistic overlap or interference.
Research dosing: Epithalon 5–10 mg/day for 10-day courses twice yearly; MOTS-C 5–10 mg three times weekly on an ongoing basis. Both are available in our longevity peptides collection.
Sourcing Stacks in India
For stack research to be valid, purity consistency across all compounds is essential. Peptide Central carries all the peptides referenced in this guide at 99% HPLC-verified purity with COA documentation. Pan-India COD delivery available for all products.